CONCOMITANT USE OF CONJUGATED ESTROGENS AND MICRONIZED PROGESTERONE INCREASED HDL-C AND TRIGLYCARIDES AND DECREASED LDL-C COMPARED TO PLACEBO AND IMPAIR GLUCOSE TOLERNCE. IT INHIBITS CYCLOSPORINE METABOLISM LEADING TO ITS TOXICITY. PHENYTOIN, RIFAMPICIN ETC MAY ENHANCE PROGESTERONE CLEARENCE AND HENCE REDUCE ITS EFFICACY AS ORAL CONTRACEPTIVE AND OTHERWISE.